Business UpdateJun 30, 2026, 05:22 PM
bioAffinity CyPath Lung Sales Up 300% in April; Partners with Philips
AI Summary
bioAffinity Technologies reported significant growth in its CyPath® Lung test, with unit sales in April increasing nearly 300% year-over-year and physician ordering sites up 69% from Q1 2025 to Q1 2026. The company announced a partnership with Philips and 4DMedical to enhance lung cancer screening for US veterans. Additionally, bioAffinity is advancing its pipeline with companion diagnostics for asthma/COPD and preclinical research for topical skin cancer treatments.
Key Highlights
- CyPath® Lung unit sales in April increased nearly 300% compared to April 2025.
- Physician offices ordering CyPath® Lung increased 69% from Q1 2025 to Q1 2026.
- Partnering with Philips and 4DMedical to enhance lung cancer screening for US veterans.
- Advancing research for companion diagnostics for asthma and COPD with Brooke Army Medical Center.
- Preclinical research supports topical treatments for basal and squamous cell carcinomas.
- Received Mexico patent allowance for CyPath® Lung technology on May 27, 2026.
Price Impact
More from BIAF